Skip to content

Study · Measured the body's own peptide · 1987

2 results

Immunoreactive vasoactive intestinal polypeptide in acinic cell carcinoma of the parotid gland.

Hayashi Y, Nishida T, Yoshida H, Yanagawa T, Yura Y, Sato M

Cancer1 Sept 1987Cited by 7 (Europe PMC)

PMID3300954 (opens in a new tab)DOI10.1002/1097-0142(19870901)60:5<962::aid-cncr2820600508>3.0.co;2-m (opens in a new tab)PepBankPUB-03300954
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In human parotid gland tumours, VIP was found immunohistochemically in acinic cell carcinomas, but not in pleomorphic adenoma, Warthin's tumour, oxyphilic adenoma, mucoepidermoid carcinoma, adenocarcinoma or adenoid cystic carcinoma.

    In plain wordsIn human parotid gland tumours, the body's own VIP was found in acinic cell carcinomas but not in the other tumour types tested.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIP immunoreactivity in parotid tumour types
    Study

    n: not reported in source

    Human parotid gland tumours
    Comparator
    Other parotid gland tumours
    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    Vasoactive intestinal polypeptide (VIP) in the neoplastic cells of acinic cell carcinomas arising in the human parotid gland was found immunohistochemically, whereas other parotid gland tumors, such as pleomorphic adenoma, Warthin's tumor, oxyphilic adenoma, mucoepidermoid carcinoma, adenocarcinoma,…

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    A comparatively high concentration of immunoreactive VIP was detected by radioimmunoassay in an acinic cell carcinoma, whereas VIP in the other tumours was undetectable.

    In plain wordsIn a human parotid tumour of the acinic cell type, the body's own VIP level was high; in other tumour types it was undetectable.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseVIP concentration by radioimmunoassay in parotid tumours
    Study

    n: not reported in source

    Human parotid gland tumours
    Comparator
    Other parotid gland tumours
    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    Moreover, a comparatively high concentration of immunoreactive VIP was detected by radioimmunoassay in an acinic cell carcinoma, whereas VIP concentration of the other tumors was undetectable.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.